Collaborating Across the Continuum™: Taking IgA Nephropathy Management to the Next Level

For physicians and nurses, please click here to view the activity and obtain CE credit. 

Program Description

Immunoglobulin (Ig) A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, and it is considered a significant cause of end-stage renal disease (ESRD) in young adults. The precise pathogenesis of IgAN remains unclear. The clinical and pathological features vary significantly between individuals and races, which makes treating IgAN challenging. In most cases, the therapeutic strategies in IgAN are optimal blood pressure control and proteinuria remission to improve the renal functions. Immunosuppressive agents, such as corticosteroids, can be considered in patients with persistent proteinuria and a high risk of renal function decline; however, they include a high toxicity profile. Various pharmacological therapeutic targets are emerging based on the evolving understanding of the autoimmune pathogenesis of the progression of IgAN, which involves the immune response, mucosal immunity, renal inflammation, complement activation, and autophagy. In this online activity, expert faculty provide information to help health care providers stay up to date on recent findings regarding the pathophysiology of IgAN, and the efficacy and safety profiles of available and emerging agents.

Target audience: Health-system pharmacists, managed care pharmacists, and specialty pharmacists

Type of activity: Application
Release date: January 31, 2023
Expiration date: January 31, 2024

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Assess the pathophysiology of the disease progression of IgAN as potential targets for novel therapy
• Summarize recent evidence-based guidelines for the management of IgAN
• Analyze recent efficacy and safety trial data on new and emerging treatment for IgAN
• Design individualized treatment plans for patients with IgAN based on principles of multidisciplinary care

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-23-023-H01-P. The activity is available for CE credit through January 31, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Richard Lafayette, MD, FACP, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: Alexion, Appellis, Calliditas, Chinook, Omeros, Otsuka, Pfizer, Travere
Consultant: Alexion, Calliditas, Chinook, GSK, Novartis, Omeros, Otsuka, Pfizer, Travere

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Whitney Simmons, APRN-CNP, IgCN

Michelle M. Richardson, PharmD, BCPS

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms